EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short-term high-dose nicotinamide treatment across glaucoma subtypes reveals increased mtDNA content and minimal metabolomic change in blood

Antoni Vallbona-Garcia, James R Tribble, Simon T Gustavsson, Birke J Benedikter, Patrick J Lindsey, Carroll Ab Webers, Hubert Jm Smeets, Gauti Jóhannesson, Theo Gmf Gorgels, Pete A Williams

Experimental Eye Research · 2026

DOI: 10.1016/j.exer.2025.110807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Eye Research, 2026. Verfasst von Antoni Vallbona-Garcia und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, Netherlands; Department of Translational Genomics, Maastricht Uni…. Hauptthemen laut MEDLINE: Niacinamide, DNA, Mitochondrial, Metabolome, Vitamin B Complex. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Alcon Research Institute, Stiftelsen Tornspiran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In glaucoma, retinal ganglion cell degeneration has been linked to declining mitochondrial metabolic capacity. Nicotinamide (NAM) supplementation has emerged as a potential treatment for this. We assessed the effects of a 2-week NAM supplementation on blood buffy coat mitochondrial content (qPCR to assess mtDNA amount per cell) and the plasma metabolome (small-molecular-weight high-resolution mass spectrometry) in 90 glaucoma subjects from 3 different glaucoma subtypes (high tension glaucoma (HTG), normal tension glaucoma (NTG), and pseudoexfoliative glaucoma (PEXG), n = 30 per group), and 30 healthy controls with similar age and sex distribution. At baseline (pre-NAM), only ethylmalonic acid, a compound related to defects in β-oxidation and mitochondrial dysfunction, was found to be modestly increased in the 3 glaucoma subtypes in comparison to controls. All groups showed a similar metabolome response to treatment with a specific increase in NAM and related species (1-methylnicotinamide, 6-hydroxynicotinamide, N1-methyl-2-pyridone-5-carboxamide), increased 5-methylcytosine, and decreased 4-pyridoxic acid. Between groups, only sarcosine had a different response, with a small reduction in HTG and NTG post-treatment. NAM treatment resulted in a significant but slight within-group increase in blood mtDNA amount in controls and HTG (12 % and 17 %, respectively). This study suggests that NAM treatment leads to similar plasma metabolome changes between glaucoma groups and controls, which predominantly reflect increased NAM metabolites and intermediates, with minimal effects on the wider metabolome, and a modest increase in mtDNA amount in HTG and controls. As this was observed in a short-term accelerated dosing context, long-term and larger studies with additional timepoints and greater adjustment for systemic metabolic factors will be required to provide more information on the long-term effects of oral NAM supplementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NiacinamideDNA, MitochondrialMetabolomeVitamin B ComplexGlaucoma, Open-AngleGlaucomaHumansMaleFemaleAgedMiddle AgedMetabolomicsIntraocular PressureMitochondria

Stichwörter der Autor:innen

Buffy coatGlaucomaMetabolismMitochondriaPseudoexfoliationmtDNA

Substanzen

NiacinamideDNA, MitochondrialVitamin B Complex

Autor:innen und Institutionen

  • University Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, Netherlands; Department of Translational Genomics, Maastricht University, Maastricht, Netherlands; Mental Health and Neuroscience Resea…
  • Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden.
  • University Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, Netherlands; Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, Netherlands.
  • Department of Translational Genomics, Maastricht University, Maastricht, Netherlands.
  • Department of Translational Genomics, Maastricht University, Maastricht, Netherlands; Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, Netherlands.

Förderung

  • Swedish Research Council
  • Alcon Research Institute
  • Stiftelsen Tornspiran
  • Knut and Alice Wallenberg Foundation
  • Ögonfonden
  • Region Västerbotten
  • Stichting Glaucoomfonds

Zitieren

APA

Vallbona-Garcia, A., Tribble, J. R., Gustavsson, S. T., Benedikter, B. J., Lindsey, P. J., Webers, C. A., Smeets, H. J., Jóhannesson, G., Gorgels, T. G., & Williams, P. A. (2026). Short-term high-dose nicotinamide treatment across glaucoma subtypes reveals increased mtDNA content and minimal metabolomic change in blood. Experimental Eye Research. https://doi.org/10.1016/j.exer.2025.110807

Vancouver

Vallbona-Garcia A, Tribble JR, Gustavsson ST, Benedikter BJ, Lindsey PJ, Webers CA, et al. Short-term high-dose nicotinamide treatment across glaucoma subtypes reveals increased mtDNA content and minimal metabolomic change in blood. Experimental Eye Research. 2026. doi:10.1016/j.exer.2025.110807

BibTeX
@article{VallbonaGarcia2026,
  author = {Vallbona-Garcia, Antoni and Tribble, James R and Gustavsson, Simon T and Benedikter, Birke J and Lindsey, Patrick J and Webers, Carroll Ab and Smeets, Hubert Jm and Jóhannesson, Gauti and Gorgels, Theo Gmf and Williams, Pete A},
  title = {Short-term high-dose nicotinamide treatment across glaucoma subtypes reveals increased mtDNA content and minimal metabolomic change in blood},
  journal = {Experimental Eye Research},
  year = {2026},
  doi = {10.1016/j.exer.2025.110807}
}
Kostenlos starten →